<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559831</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-319</org_study_id>
    <nct_id>NCT01559831</nct_id>
  </id_info>
  <brief_title>Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination</brief_title>
  <official_title>Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IC51-319 is a single-arm, open-label study that investigates immune responses in subjects&#xD;
      undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during&#xD;
      primary immunization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IC51-319 is a single-arm, open-label study that investigates immune responses in subjects&#xD;
      undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during&#xD;
      primary immunization.&#xD;
&#xD;
      A total of up to 50 subjects having received primary immunization of IXIARO batch JEV09L37&#xD;
      and who have not yet been revaccinated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate (SCR) at Day 28</measure>
    <time_frame>at Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCR at Day 0</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer at Day 0 and 28</measure>
    <time_frame>Day 0 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events up to Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>IXIARO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IXIARO, applied according to licensed dose, intramuscular</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IXIARO</intervention_name>
    <description>Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular</description>
    <arm_group_label>IXIARO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 18 years or older having received IXIARO batch JEV09L37 during primary&#xD;
             immunization&#xD;
&#xD;
          -  In female subjects, either childbearing potential terminated by surgery or 1 year&#xD;
             post-menopausal, or a negative urine pregnancy test during screening and the&#xD;
             willingness not to become pregnant during the entire study period by practicing&#xD;
             reliable methods of contraception&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to any study-related&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vaccination against Yellow fever, Dengue Fever, West Nile Fever or TBE or vaccination&#xD;
             with any JE vaccine since primary immunization with IXIARO JEC09L37&#xD;
&#xD;
          -  Clinical manifestation of any flavivirus infection since primary immunization with&#xD;
             IXIARO JEC09L37&#xD;
&#xD;
          -  Acute febrile infections or exacerbation of chronic infection on the day of IXIARO&#xD;
             vaccination&#xD;
&#xD;
          -  Pregnancy, lactation or unreliable contraception in female subjects with child-bearing&#xD;
             potential and unreliable contraception in male subjects.&#xD;
&#xD;
          -  Use of any other investigational or non-registered drug within 30 days prior to the&#xD;
             first vaccination with IXIARO Visit 1 and during the study period&#xD;
&#xD;
          -  Any condition which might interfere with study objectives or would limit the subject's&#xD;
             ability to complete the study in the opinion of the investigator&#xD;
&#xD;
          -  Persons who are committed to an institution&#xD;
&#xD;
          -  At Day 0, upcoming scheduled travel to a JE endemic region&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Kadlecek, Mag.</last_name>
    <role>Study Chair</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLH Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>IXIARO</keyword>
  <keyword>Japanese Encephalitis Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

